

Familial Breast Cancer SM2 minutes

Familial Breast Cancer update – Scoping meeting 2 minutes

Date: 21/10/2025

Location: Virtual

Minutes: Final

Committee members present:

Alison Cameron	Chair	Present for items 1-7
Kay Davies-Crowley	Advanced Nurse Specialist	Present for items 1-7
Rachael Griffin	Co-opted Lay member	Present for items 1-7
Helen Hanson	Clinical Geneticist	Present for items 1-7
Ashley Hurst	Lay member	Present for items 1-7
Zoe Kemp	Clinical Geneticist	Present for items 1-7
Sarah Pugh	Genetic Counsellor	Present for items 1-3
Kathryn Rigby	Breast Surgeon	Present for items 1-7
Tamsin Sargeant	Lay member	Present for items 1-7
Hannah Seabrook	Clinical Psychologist	Present for items 1-7
Liz Sherwin	Clinical Oncologist	Present for items 1-7

In attendance NICE:

Sarah Boyce	Senior Technical Analyst	Present for items 1-7
Jeremy Braybrooke	Clinical Adviser	Present for items 1-7
Victoria Carter	Implementation Lead	Present for items 1-4
Danielle Conroy	Project Manager	Present for items 1-7
Gareth Haman	Senior Guidance Content Designer	Present for items 3-7
Marie Harrisingh	Topic Lead	Present for items 1-7
Tzujung Lai	Health Economist	Present for items 1-7
Sarah Matthews	Technical Analyst	Present for items 1-7
Lina Manounah	Technical Analyst	Present for items 1-7
Eric Slade	Health Economics Adviser	Present for items 1-7
Daniel Tuvey	Information Specialist	Present for items 1-3
Magda Watras	Pharmacist Clinical Adviser	Present for items 1-7

Apologies:

Sadaf Haque	General Practitioner, Committee
-------------	---------------------------------

1. Welcome, Introductions and apologies
<p>The Chair, Alison Cameron (AC) welcomed the committee members and NICE attendees to scoping meeting 2 for the NICE Familial Breast Cancer guideline update which will focus on initial assessment and genetic testing.</p> <p>Apologies were noted and the group introduced themselves.</p>
2. Overview of stakeholder comments
<p>The Chair introduced Sarah Matthews (SM), Technical Analyst who reminded committee members of the guideline areas we plan to update, and the 6 questions included in the scope.</p> <p>SM advised how many comments had been received and from which organisations. SM outlined the key themes that came out of stakeholder feedback.</p>
3. Discussion of comments by theme <ul style="list-style-type: none">• Polygenic risk scores• Population
<p>SM then started to go through the comments which required committee input by theme.</p> <p>The committee started by considering comments surrounding polygenic risk scores before moving on to population.</p> <p>The committee were reminded what populations were currently in scope and were asked to consider several sub-themes including the populations to be covered by the work on risk groups, carrier probability and genetic testing.</p> <p>The committee had the opportunity to discuss what was being presented and ask questions.</p> <p>The Chair thanked SM for her input.</p>
4. Discussion of comments by theme (continued) <ul style="list-style-type: none">• Information and emotional needs• Surveillance
<p>The Chair introduced Lina Manounah (LM), Technical Analyst who presented the comments which raised questions about information and emotional needs and then surveillance.</p> <p>The committee considered counselling, information provisions and emotional support. They also discussed the subthemes identified around surveillance which included implementation, surveillance methods, risk subclassification and risk prediction.</p> <p>The committee had the opportunity to discuss as a group and offer their expert input on specific questions from the NICE team in these areas.</p>

The Chair thanks LM for her input.
5. Discussion of comments by theme (continued) <ul style="list-style-type: none">• Contraception• Other issues
<p>SM then led the committee discussion on the final theme of contraception.</p> <p>The committee were reminded of the original recommendations around contraception in CG164 and considered the points raised about contraception in the current consultation.</p> <p>The committee then moved on to considering other issues which were raised by stakeholders including service provision, cascade testing, risk-based mastectomy and the wider impact on other guidelines.</p> <p>The Chair thanked the committee for their input.</p> <p>The NICE team will use the committee discussion from today to make appropriate revisions to the scope and draft responses to the consultation comments.</p>
6. Equality and health inequalities assessment
<p>The Chair introduced Marie Harrisingh (MH), Topic Lead who provided an overview of the new equality and health inequality issues that had been raised by stakeholders. These will be captured in the equality and health inequality assessment to support this update.</p> <p>AC thanked MH for her contribution.</p>
7. AOB and close
<p>AC summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, AC brought the meeting to a close.</p>

Date of next meeting: 11th December 2025

Location of next meeting: London